A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
NCT ID: NCT00332176
Last Updated: 2008-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2006-06-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Celgosivir
400mg qd + standard of care for 12 weeks
2
Celgosivir
600mg qd + standard of care for 12 weeks
3
Peginterferon alfa 2b + ribavirin
Standard of care for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celgosivir
400mg qd + standard of care for 12 weeks
Celgosivir
600mg qd + standard of care for 12 weeks
Peginterferon alfa 2b + ribavirin
Standard of care for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* primary diagnosis of chronic HCV infection, genotype 1
* Interferon-based treatment-naïve
* Body Mass Index of 18 to 30, inclusive
Exclusion Criteria
* patients with diabetes mellitus
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioWest Therapeutics Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MIGENIX Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jim Pankovich
Role: STUDY_DIRECTOR
BioWest Therapeutics Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liver and Intestinal Research Centre
Vancouver, British Columbia, Canada
Cantest
Vancouver, British Columbia, Canada
Biovail Contract Research
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Jim Pankovich
Role: CONTACT
Phone: 604-221-9666
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCV-06-001
Identifier Type: -
Identifier Source: org_study_id